Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Today's Bonus Story
This 4/20, Wall Street Is Betting on More Than MarijuanaBy Jeffrey Neal Johnson. Posted: 4/20/2026. 
Key Points
- A new executive order fast-tracking psychedelic medicines triggered single-session gains of roughly 40% for Compass Pathways and over 20% for Atai Beckley.
- The cannabis sector has shifted away from speculative policy bets, with Curaleaf and Innovative Industrial Properties rewarding shareholders through buybacks and dividends.
- A barbell strategy pairing high-growth psychedelic stocks against cash-generating cannabis operators could help balance risk and return in the alternative medicine space.
- Special Report: Elon’s “Hidden” Company
While many investors were focused on the annual 4/20 holiday and the usual buzz around marijuana stocks, a quiet revolution unfolded in Washington. Over a weekend when markets were closed, the administration issued an executive order designed to fast-track psychedelic medicines to market. This catalyst has split the alternative drug sector into two distinct camps. It created a dynamic that separates high-octane growth opportunities from mature, value-oriented plays, leaving unprepared investors to navigate a rapidly transformed landscape.
Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision.
Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now. Discover the real reason behind the Iran strikes before markets react
The market used to treat this entire space as one big, speculative bet on drug reform. That playbook is now obsolete. Today, a clear, bifurcated strategy has emerged for those looking to capitalize on the future of alternative medicine. From Trials to Takeoff: The FDA Fast-Track Ignites a RallyThe market’s reaction to the weekend news was immediate and forceful. Compass Pathways PLC (NASDAQ: CMPS), a leader in psilocybin therapy research, jumped roughly 40% in a single session. Similarly, Atai Beckley (NASDAQ: ATAI), which develops a diverse portfolio of mental health treatments, rose by more than 20%. These explosive moves were amplified by a classic short-squeeze dynamic. Prior to the announcement, many institutional investors were betting against these stocks, borrowing shares to sell them in the hope of buying them back later at a lower price. Short interest in Compass Pathways had reached nearly 10% of its public float. The unexpected good news prompted short sellers to buy back shares and close losing positions, and that forced buying pushed the stock sharply higher. Atai Beckley had a similar short interest of about 9.2%, suggesting it too was ripe for a short squeeze. For investors, the administration's policy directly addresses the primary risk in biotechnology: cash burn. Clinical trials are long and expensive. By creating a faster path to commercialization, the government effectively shortens the period these companies must spend burning capital before generating revenue. That shift de-risks the path to profitability by reducing the need for future dilutive financing and accelerating the timeline to potential positive cash flow. The bull case is that, with this regulatory tailwind, the conversation shifts from whether these companies can get their treatments to market to how quickly. The next 12 to 18 months could see firms like Compass and Atai accelerate their New Drug Application (NDA) submissions to the Food and Drug Administration. An NDA is the formal submission a drug sponsor makes to ask the FDA to consider approving a new drug for marketing and sale. Securing an expedited review puts these companies on a direct course to commercial partnerships and to tapping into a multibillion-dollar mental health market targeting conditions such as treatment-resistant depression and PTSD. Still, investors should remember these are largely pre-revenue companies, and ultimate success depends on positive clinical outcomes and solid commercial execution. Cannabis Grows Up: The New Focus on Profits, Not PolicyWhile psychedelic stocks were launching, the legacy cannabis sector experienced a much more subdued 4/20. The AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS), a broad gauge of the industry, posted only a modest bump. That muted reaction signals a critical evolution: the sector no longer trades solely on speculative legalization hopes. Instead, the market is rewarding tangible business fundamentals and shareholder returns. The real story in cannabis now lies with operators generating meaningful cash for investors. Consider these signs of corporate maturity:
Curaleaf Holdings (OTCMKTS: CURLF), a global revenue leader that reported over $333 million in its most recent quarter, announced a substantial share buyback program. For investors, a buyback signals management's confidence and reduces shares outstanding, which can increase earnings per share. Innovative Industrial Properties (NYSE: IIPR) operates as a real estate investment trust (REIT) that buys properties and leases them to licensed cannabis operators. That landlord model insulates IIPR from the volatility of plant-touching businesses, allowing it to generate over $111 million in profit and reward shareholders with a robust 14% dividend yield. The primary risk for cannabis investors has long been the slow pace of federal policy reform. Companies like Curaleaf and IIPR are mitigating that risk by creating shareholder value today. Looking ahead, the administration's favorable stance on alternative medicines suggests the next logical catalysts are federal descheduling of cannabis and passage of banking reform. Such legislation would clear the path for industry giants to uplist from over-the-counter (OTC) markets to major U.S. exchanges like the NASDAQ. An uplisting is a major validation that can dramatically increase liquidity and make a stock available to a much larger pool of institutional investors and mutual funds. Balancing the Buzz: A Strategy for Psychedelics and CannabisThe alternative drug market now presents two distinct and compelling paths. The weekend’s policy shockwave has supercharged the psychedelic sector, creating an explosive, policy-driven growth opportunity. In contrast, the cannabis sector has matured into value plays focused on generating cash and rewarding shareholders. This bifurcation lends itself to a barbell strategy: concentrate a portfolio on two extremes—high-growth speculation and stable value—with little in the middle. The high-growth potential of psychedelic stocks like Compass and Atai Beckley represents one side of the barbell. The other is anchored by the stability and cash flow of established cannabis operators like Curaleaf and IIPR. Ultimately, how an investor approaches this new landscape will depend on their strategy and risk tolerance. Those with higher risk tolerance and a growth focus may find the policy-driven momentum in psychedelics compelling. Investors seeking value, income, and tangible fundamentals may prefer established cannabis companies that are already generating profits and returning capital to shareholders. |
Tiada ulasan:
Catat Ulasan